Changeflow GovPing Pharma & Drug Safety In Vitro Bioproduction of Polyhydroxyalkanoate ...
Routine Notice Added Final

In Vitro Bioproduction of Polyhydroxyalkanoate Monomers

Favicon for changeflow.com USPTO Patent Applications - Biotech (C12N)
Published
Detected
Email

Summary

USPTO published patent application US20260098283A1 by inventor Stephen Quirk for an enzymatic process to produce homogeneous chain length polyhydroxyalkanoate (PHA) monomers and polymers with chain lengths of at least eight carbons from long-chain fatty acids. The process enables specific, controlled production of PHA materials through in vitro enzyme contact with long-chain fatty acid precursors.

What changed

USPTO published patent application US20260098283A1 disclosing an enzymatic process for producing homogeneous chain length polyhydroxyalkanoate (PHA) monomers and polymers with chain lengths of at least eight carbons from long-chain fatty acid precursors. The invention enables specific PHA material production through in vitro enzyme contact.

For biotechnology and pharmaceutical manufacturers, this patent application represents potential intellectual property that may affect future product development strategies involving biodegradable polymers or PHA-based materials. Companies in these sectors should monitor prosecution of this application to assess potential licensing needs or competitive implications.

What to do next

  1. Monitor for patent grant status updates

Archived snapshot

Apr 13, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

In Vitro Bioproduction of Specific Chain Legnth Poly(hydroxyalkanoate) Monomers

Application US20260098283A1 Kind: A1 Apr 09, 2026

Inventors

Stephen Quirk

Abstract

An enzymatic process and system are disclosed for producing homogeneous chain length poly hydroxyalkanoate monomers and/or polymers having a chain length of at least eight carbons from a long-chain fatty acid or precursor thereof. The process also results in specific homogenous chain length polyhydroxyalkanoate monomers and/or polymers. The long-chain fatty acid or precursor thereof can be contacted in vitro with an enzyme or a mixture of enzymes to produce the homogeneous chain length polyhydroxyalkanoate.

CPC Classifications

C12P 7/6418 C12N 9/0006 C12N 9/0008 C12N 9/001 C12N 9/0077 C12N 9/1029 C12N 9/88 C12N 9/93 C12P 7/6427 C12Y 101/01135 C12Y 101/01136 C12Y 101/01211 C12Y 101/99002 C12Y 103/08008 C12Y 114/15003 C12Y 402/01017 C12Y 602/01003

Filing Date

2023-09-28

Application No.

19115062

View original document →

Get daily alerts for USPTO Patent Applications - Biotech (C12N)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 9th, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
US20260098283A1

Who this affects

Applies to
Manufacturers Pharmaceutical companies
Industry sector
3254.1 Biotechnology
Activity scope
Patent application Biopolymers manufacturing
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Biotechnology Environmental Protection

Get alerts for this source

We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!